Article
Pharmacology & Pharmacy
Ayad A. Al-Hamashi, Dongxing Chen, Youchao Deng, Guangping Dong, Rong Huang
Summary: This study reported the design and synthesis of bisubstrate analogues for PRMTs, with compound AH237 showing potent and selective inhibition towards PRMT4 and PRMT5. Computational studies provided insights into the high potency and selectivity of AH237, offering a valuable strategy for developing inhibitors for PRMTs in the future.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Oncology
Anthony B. B. El-Khoueiry, James Clarke, Tobias Neff, Tim Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido-Laguna, Emiliano Calvo, Jordi Rodon, Ben Tran, Peter J. J. O'Dwyer, Adam Cuker, Albiruni R. Abdul R. Razak
Summary: GSK3368715, a reversible inhibitor of type I protein methyltransferases, showed anticancer activity in preclinical studies. This Phase 1 study evaluated its safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors. However, due to a higher-than-expected incidence of thromboembolic events, the study was terminated.
BRITISH JOURNAL OF CANCER
(2023)
Article
Cell Biology
Yachun Jia, Xiao Yu, Rui Liu, Luyi Shi, Hua Jin, Dan Yang, Xiaofeng Zhang, Ying Shen, Yuandong Feng, Peihua Zhang, Yi Yang, Linlin Zhang, Pengyu Zhang, Zongfang Li, Aili He, Guangyao Kong
Summary: Epigenetic modifications, particularly the expression of protein arginine methyltransferase 1 (PRMT1), play a crucial role in the pathogenesis of multiple myeloma (MM). High expression of PRMT1 in MM patients is positively correlated with MM stages and adverse prognosis. Silencing PRMT1 inhibits MM cell proliferation and tumorigenesis through downregulation of oxidative phosphorylation (OXPHOS) and the methylation of NDUFS6. Furthermore, the combination of PRMT1 inhibitor and bortezomib shows synergy in inhibiting MM progression.
CELL DEATH & DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Misuzu Hashimoto, Akiyoshi Fukamizu, Tsutomu Nakagawa, Yasuhiko Kizuka
Summary: PRMT1 is crucial for the development of neurons, astrocytes, and oligodendrocytes, requiring further investigation. The relevance of PRMT1 in neurodegenerative diseases will continue to be a hot topic.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
(2021)
Article
Chemistry, Analytical
Zhen Liu, Keyun Wang, Mingliang Ye
Summary: In order to understand the function of protein arginine methyltransferases(PRMTs), it is crucial to identify their substrate proteins. However, this is challenging due to the dominance of stable and strong interacting proteins over weak and transient substrate proteins. In this study, a novel photoreactive probe-based strategy was developed to identify the substrate proteins of methyltransferases, specifically PRMT1. This strategy effectively distinguished substrate proteins from other interacting proteins and allowed the identification of highly confident substrate proteins. Importantly, it was discovered that hypomethylation of proteins is a prerequisite for efficient capturing of substrate proteins. This study describes the development of a robust chemical proteomic tool for profiling transient substrates and has broad biomedical applications.
ANALYTICAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Fang-Zhi Yan, Hui Qian, Fang Liu, Chen-Hong Ding, Shu-Qing Liu, Meng-Chao Xiao, Shi-Jie Chen, Xin Zhang, Cheng Luo, Wei-Fen Xie
Summary: PRMT1 plays a vital role in hepatic fibrogenesis by promoting HSC activation. Inhibition of PRMT1 can mitigate hepatic fibrosis by attenuating HSC activation.
Article
Pharmacology & Pharmacy
Vijay Raj, Suganya Natarajan, C. Marimuthu, Suvro Chatterjee, Mohankumar Ramasamy, Ganesh Munuswamy Ramanujam, Mariadhas Valan Arasu, Naif Abdullah Al-Dhabi, Ki Choon Choi, Jesu Arockiaraj, Kanchana Karuppiah
Summary: The combination treatment with MET and VD blocked LPS-induced endothelial cell methyltransferase activity, senescence, and dysfunction. The study identified a previously unknown function of the test compounds in inhibiting adverse cellular events through SIRT1 and PRMT1.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Iredia D. Iyamu, Ayad A. Al-Hamashi, Rong Huang
Summary: In this study, a potent pan-inhibitor II757 for PRMTs was designed and synthesized, showing high inhibition for various PRMTs and competitively binding at the SAM binding site of PRMT1. II757 also exhibited selectivity for PRMTs over other methyltransferases, serving as a general probe and a lead for further optimization.
Article
Oncology
Shuangjie Liu, Zhuonan Liu, Chiyuan Piao, Zhe Zhang, Chuize Kong, Lei Yin, Xi Liu
Summary: The study reveals PRMT5 as a therapeutic target for bladder cancer and identifies FKA, extracted from the kava plant, as an inhibitor of PRMT5 for the treatment of bladder cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Chemistry, Medicinal
Yudao Shen, Fengling Li, Magdalena M. Szewczyk, Levon Halabelian, Irene Chau, Mohammad S. Eram, Carlo Dela Sena, Kwang-Su Park, Fanye Meng, He Chen, Hong Zeng, Aiping Dong, Hong Wu, Viacheslav V. Trush, David McLeod, Carlos A. Zepeda-Velazquez, Robert M. Campbell, Mary M. Mader, Brian M. Watson, Matthieu Schapira, Cheryl H. Arrowsmith, Rima Al-Awar, Dalia Barsyte-Lovejoy, H. Umit Kaniskan, Peter J. Brown, Masoud Vedadi, Jian Jin
Summary: (R)-2 is a potent and highly selective inhibitor of PRMT6, binding to an induced allosteric pocket. It shows outstanding selectivity for PRMT6 over other methyltransferases and can be used as a valuable tool for further investigation of PRMT6 functions in health and disease.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Endocrinology & Metabolism
Seri Choi, Dahee Choi, Yun-Kyung Lee, Seung Hyun Ahn, Je Kyung Seong, Sung Wook Chi, Tae Jung Oh, Sung Hee Choi, Seung-Hoi Koo
Summary: PRMT1 plays a crucial role in maintaining metabolic balance in adipose tissues, with its depletion leading to increased lipid catabolism and adverse effects in conditions of high-fat diet or obesity, such as promotion of adipose tissue inflammation and ectopic accumulation of triglycerides.
Article
Hematology
Malini Rethnam, Darren Qiancheng Tan, Shi Hao Tan, Jia Li, Rui Yokomori, Ying Li, Henry Yang, Takaomi Sanda, Toshio Suda
Summary: The rare and aggressive hematologic malignancy BPDCN is highly sensitive to PRMT5 inhibition, which not only inhibits cell growth but also mitigates tumor progression. The inhibition of PRMT5 affects the function of key RNA methylation gene METTL3, leading to increased interferon signaling and attenuated sensitivity to PRMT5 inhibition.
Article
Biochemistry & Molecular Biology
Qin Wu, David Y. Nie, Wail Ba-alawi, YiShuai Ji, ZiWen Zhang, Jennifer Cruickshank, Jillian Haight, Felipe E. Ciamponi, Jocelyn Chen, Shili Duan, Yudao Shen, Jing Liu, Sajid A. Marhon, Parinaz Mehdipour, Magdalena M. Szewczyk, Nergiz Dogan-Artun, WenJun Chen, Lan Xin Zhang, Genevieve Deblois, Panagiotis Prinos, Katlin B. Massirer, Dalia Barsyte-Lovejoy, Jian Jin, Daniel D. De Carvalho, Benjamin Haibe-Kains, XiaoJia Wang, David W. Cescon, Mathieu Lupien, Cheryl H. Arrowsmith
Summary: This study identified an inhibitor called MS023 that has antitumor growth activity in triple-negative breast cancer (TNBC). Activation of interferon responses was found to be a functional biomarker and determinant of response in TNBC cell lines and human-derived organoids. Inhibition of type I PRMT triggers an interferon response through the antiviral defense pathway.
NATURE CHEMICAL BIOLOGY
(2022)
Article
Oncology
Noelia Che, Kai-Yu Ng, Tin-Lok Wong, Man Tong, Phillis W. F. Kau, Lok-Hei Chan, Terence K. Lee, Michael S. Y. Huen, Jing-Ping Yun, Stephanie Ma
Summary: Autophagy plays a critical role in cancer cells such as hepatocellular carcinoma (HCC), and deficiency of the post-translational modification enzyme PRMT6 promotes autophagy induction in HCC under stress conditions. PRMT6 interacts with and methylates BAG5 to regulate HSC70 stability, influencing autophagy in HCC cells. Targeting BAG5 may be a promising strategy in HCC treatment to suppress autophagy and enhance sensitivity to sorafenib.
Review
Medicine, Research & Experimental
Jiaoyang Ning, Liu Chen, Gang Xiao, Yu Zeng, Wen Shi, Guilong Tanzhu, Rongrong Zhou
Summary: PRMTs are involved in the prognosis and metastasis of tumors, and their regulation of molecular mechanisms affects tumor metastasis. Inhibiting arginine methylation can reduce tumor metastasis, and this field holds promise for clinical application.
BIOMEDICINE & PHARMACOTHERAPY
(2023)